Page last updated: 2024-12-07
homoanatoxin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
homoanatoxin: structure given in first source; potent nicotinic agonist; analog of anatoxin-a from Cyanobacteria [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 126727 |
MeSH ID | M0198042 |
Synonyms (10)
Synonym |
---|
homoanatoxin |
(1r)-1-(9-azabicyclo(4.2.1)non-2-en-2-yl)-1-propanone |
1-propanone, 1-(9-azabicyclo(4.2.1)non-2-en-2-yl)-, (1r)- |
2-(propan-1-oxo-1-yl)-9-azabicyclo(4.2.1)non-2-ene |
homoantx |
142926-86-1 |
homoanatoxin a |
DTXSID00931683 |
1-[(1r,6r)-9-azabicyclo[4.2.1]non-2-en-2-yl]propan-1-one |
homoanatoxin-a |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Dose-response data suggested about the same range of toxicity of FBS and FLI samples (EC50 = 0." | ( Pharmacological studies confirm neurotoxic metabolite(s) produced by the bloom-forming Cylindrospermopsis raciborskii in Hungary. Farkas, A; Győri, J; Kovács, AW; Szabó, H; Vasas, G; Vehovszky, Á, 2015) | 0.42 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (31)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (9.68) | 18.2507 |
2000's | 13 (41.94) | 29.6817 |
2010's | 13 (41.94) | 24.3611 |
2020's | 2 (6.45) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 16.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.72) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 31 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |